Novo Nordisk said that simeglutide reached the main end point in the STEP Young phase 3 clinical trial. Compared with placebo, it can reduce the BMI of obese children aged 6 to 12. After 68 weeks of treatment, 40.4% of children in the simeglutide group were no longer classified as obese, compared to 0% in the placebo group. More than 85% of enrolled children had severe grade II or III obesity at baseline. The safety characteristics of simeglutide were consistent with previous results in adult and adolescent trials, and no new safety issues were found.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.